This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

This study has been completed.
Information provided by (Responsible Party):
Paratek Pharmaceuticals Inc Identifier:
First received: February 19, 2015
Last updated: July 6, 2016
Last verified: July 2016
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.

Condition Intervention Phase
Bacterial Infections Skin Structures and Soft Tissue Infections Drug: Omadacycline Drug: Linezolid Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Resource links provided by NLM:

Further study details as provided by Paratek Pharmaceuticals Inc:

Primary Outcome Measures:
  • Early Clinical response, defined as survival with at least a 20% reduction of ABSSSI lesion size compared to screening measurements. [ Time Frame: 48-72 hours ]
  • Investigator assessment of clinical response, defined as survival and resolution or improvement of signs and symptoms at the post treatment evaluation visit [ Time Frame: 7-14 days after the last day of therapy ]

Secondary Outcome Measures:
  • Safety and tolerability as assessed by adverse events, vital sign measurements, ECGs, and lab values [ Time Frame: 0-37 days ]

Estimated Enrollment: 650
Study Start Date: June 2015
Study Completion Date: May 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omadacycline
Omadacycline IV; Omadacycline tablets
Drug: Omadacycline
Injection for IV dosing; Tablets for oral dosing
Active Comparator: Linezolid
Linezolid IV; Linezolid tablets
Drug: Linezolid
Infusion solution for IV dosing; Tablets for oral dosing
Other Name: Zyvox


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients, ages 18 years or older who have signed the informed consent
  • Has a qualifying skin and skin structure infection
  • Female patients must not be pregnant at the time of enrollment
  • Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug

Exclusion Criteria:

  • Infections where the outcome is strongly influenced by factors other than protocol-defined treatment and procedures, that require antibacterial treatment for greater than 14 days
  • Evidence of significant immunological disease
  • Severe sepsis or septic shock
  • Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid
  • Has received an investigational drug within past 30 days
  • Women who are pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02378480

  Show 78 Study Locations
Sponsors and Collaborators
Paratek Pharmaceuticals Inc
  More Information

Responsible Party: Paratek Pharmaceuticals Inc Identifier: NCT02378480     History of Changes
Other Study ID Numbers: PTK0796-ABSI-1108
Study First Received: February 19, 2015
Last Updated: July 6, 2016

Additional relevant MeSH terms:
Communicable Diseases
Bacterial Infections
Soft Tissue Infections
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017